Featured Articles

  1. Perfusion Filter Improves Cell Retention In Xuri Cell Expansion System 7/21/2022

    A new 1.2 μm pore size filter was validated for use in the Xuri Cell Expansion System W25, which decreased T cell loss, ultimately leading to higher T cell retention in the Xuri brand Cellbag bioreactor.

  2. Tips For Successfully Scaling Your cGMP Manufacturing 6/23/2022

    What are the specific obstacles to expanding manufacturing capacity? Cell therapy industry leaders share what to look for in a solutions provider and recommendations for navigating your road ahead.

  3. Step Up To GMP Manufacturing Or Outsource To A CDMO 6/1/2022

    Explore key factors to help you determine which strategy best suits your process, product, and team, as well as some general considerations and tips for succeeding in GMP manufacturing.

  4. Unlocking The Full Potential Of Genomic Medicine 6/1/2022

    There are two key challenges to realizing the potential of genomic medicines, but potential technological solutions are on the horizon, and we examine each.

  5. mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations 6/1/2022

    Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

  6. Fueling The Genetic Revolution With cGMP Manufacturing And Training 5/20/2022

    ElevateBio, in collaboration with Cytiva, is forging a path forward with a solution to de-risk the development of novel therapies, helping to speed the delivery of new CGTs and regenerative medicines.

  7. Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications 4/18/2022

    Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.

  8. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

  9. Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs 4/18/2022

    This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.

  10. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

    We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.